CN114249701A - 一种钆特醇化合物的晶型及其制备方法 - Google Patents
一种钆特醇化合物的晶型及其制备方法 Download PDFInfo
- Publication number
- CN114249701A CN114249701A CN202210000888.3A CN202210000888A CN114249701A CN 114249701 A CN114249701 A CN 114249701A CN 202210000888 A CN202210000888 A CN 202210000888A CN 114249701 A CN114249701 A CN 114249701A
- Authority
- CN
- China
- Prior art keywords
- gadoteridol
- compound
- crystal form
- degrees
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 87
- -1 gadoteridol compound Chemical class 0.000 title claims abstract description 82
- 229960005451 gadoteridol Drugs 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 4
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- FITVQUMLGWRKKG-UHFFFAOYSA-N 2-methyl-2-propoxypropane Chemical compound CCCOC(C)(C)C FITVQUMLGWRKKG-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 238000002441 X-ray diffraction Methods 0.000 description 37
- 238000012360 testing method Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- OOMMCMLNMBRPLT-UHFFFAOYSA-N anisole;propan-2-yl acetate Chemical compound CC(C)OC(C)=O.COC1=CC=CC=C1 OOMMCMLNMBRPLT-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- MTWSTCXAJXEKJQ-UHFFFAOYSA-N ethyl acetate;2-methoxy-2-methylpropane Chemical compound CCOC(C)=O.COC(C)(C)C MTWSTCXAJXEKJQ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940075613 gadolinium oxide Drugs 0.000 description 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical group [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
峰序号 | 2θ(°) | 相对强度(%) |
1 | 7.941 | 79.9 |
2 | 8.58 | 66 |
3 | 8.921 | 31.1 |
4 | 10.038 | 53.4 |
5 | 10.962 | 30.2 |
6 | 11.279 | 100 |
7 | 11.66 | 65.8 |
8 | 12.502 | 21.5 |
9 | 13.042 | 15.6 |
10 | 13.558 | 20.1 |
11 | 13.922 | 19.1 |
12 | 14.099 | 34.4 |
13 | 14.38 | 10.7 |
14 | 14.777 | 11.3 |
15 | 16.024 | 15.1 |
16 | 16.522 | 15.6 |
17 | 16.718 | 10.3 |
18 | 17.862 | 24 |
19 | 23.763 | 10.6 |
20 | 24.159 | 10.3 |
21 | 25.459 | 11.7 |
22 | 26.665 | 13.6 |
23 | 27.183 | 10.6 |
24 | 30.804 | 11.2 |
峰序号 | 2θ(°) | 相对强度(%) |
1 | 8.6 | 100 |
2 | 10.042 | 56.1 |
3 | 10.958 | 10.7 |
4 | 12.516 | 23.5 |
5 | 13.057 | 17 |
6 | 13.94 | 19.3 |
7 | 14.083 | 17.5 |
8 | 14.781 | 10.6 |
实施例 | 醚类有机溶剂 | 酯类有机溶剂 | 收率 |
3 | 甲基叔丁基醚 | 乙酸乙酯 | 95% |
4 | 正丙基叔丁基醚 | 乙酸丁酯 | 91% |
5 | 苯甲醚 | 乙酸异丙酯 | 88% |
6 | 二苯醚 | 苯甲酸乙酯 | 84% |
钆特醇化合物晶型 | 80℃干燥放置24小时 | 25℃,60%RH放置10天 | 40℃,75%RH放置10天 |
晶型A | XRD不变 | XRD改变 | XRD改变 |
晶型B | XRD不变 | XRD不变 | XRD不变 |
钆特醇化合物晶型 | 室温时在水中溶解度 | 溶解度分类 |
晶型A | 40-60mg/mL | 溶解 |
晶型B | 200-300mg/mL | 易溶 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210000888.3A CN114249701A (zh) | 2022-01-04 | 2022-01-04 | 一种钆特醇化合物的晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210000888.3A CN114249701A (zh) | 2022-01-04 | 2022-01-04 | 一种钆特醇化合物的晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114249701A true CN114249701A (zh) | 2022-03-29 |
Family
ID=80796117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210000888.3A Pending CN114249701A (zh) | 2022-01-04 | 2022-01-04 | 一种钆特醇化合物的晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114249701A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108084105A (zh) * | 2016-11-23 | 2018-05-29 | 四川科伦药物研究院有限公司 | 钆特醇中间体及其合成方法和利用该钆特醇中间体制备钆特醇的方法 |
CN109705104A (zh) * | 2019-01-28 | 2019-05-03 | 湖北天舒药业有限公司 | 钆系离子型造影剂中间体的制备方法及其应用 |
WO2019143073A1 (ko) * | 2018-01-19 | 2019-07-25 | 주식회사 엔지켐생명과학 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
CN110835326A (zh) * | 2018-08-15 | 2020-02-25 | 正大天晴药业集团股份有限公司 | 大环螯合剂及其中间体的制备方法 |
-
2022
- 2022-01-04 CN CN202210000888.3A patent/CN114249701A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108084105A (zh) * | 2016-11-23 | 2018-05-29 | 四川科伦药物研究院有限公司 | 钆特醇中间体及其合成方法和利用该钆特醇中间体制备钆特醇的方法 |
WO2019143073A1 (ko) * | 2018-01-19 | 2019-07-25 | 주식회사 엔지켐생명과학 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
CN110835326A (zh) * | 2018-08-15 | 2020-02-25 | 正大天晴药业集团股份有限公司 | 大环螯合剂及其中间体的制备方法 |
CN109705104A (zh) * | 2019-01-28 | 2019-05-03 | 湖北天舒药业有限公司 | 钆系离子型造影剂中间体的制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112638873B (zh) | 吲哚菁绿的精制方法 | |
WO2016201905A1 (zh) | 一种头孢呋辛钠的新型工业结晶方法及其制剂 | |
CN114249701A (zh) | 一种钆特醇化合物的晶型及其制备方法 | |
CN112538123B (zh) | 一种舒更葡糖钠晶型m | |
CN108778282A (zh) | 一种GnRH受体拮抗剂的结晶形式及其制备方法 | |
CN107188800B (zh) | 具有晶型a形式的甜菊醇晶体、其制备方法及应用 | |
CN101347412B (zh) | 三水合氨磷汀结晶冻干制剂及其制备方法 | |
CN116041351A (zh) | 盐酸咪达唑仑新晶型及其制备方法 | |
CA2961819C (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
WO2017028762A1 (zh) | 一种萘环化合物的晶型 | |
CN106432279A (zh) | 一种制备治疗外科手术感染的药物头孢曲松钠晶体化合物的方法 | |
CN106432274A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN106432278A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN107337683B (zh) | 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用 | |
CN105646674A (zh) | 一种达巴万星化合物 | |
WO2021136491A1 (zh) | 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途 | |
CN106279367B (zh) | 一种醋酸阿托西班晶体及其制备方法 | |
CN114436928A (zh) | 一种维纳卡兰盐酸盐晶型a及其制备方法 | |
CN113845529B (zh) | 一种头孢氨苄共晶化合物及其制备方法 | |
CN109369425B (zh) | 非诺贝特酸胆碱盐的制备方法 | |
CN106831822A (zh) | 一种盐酸头孢替安晶体化合物及其制备方法 | |
CN107987016B (zh) | 化合物n-丁基-2,2’-亚氨基-双(8-喹啉胺)的晶体、药物组合物及其应用 | |
DE60022487T2 (de) | In vivo färbemittel und verwendungsmethoden zur identifizierung von dysplastischem gewebe | |
CN106749058B (zh) | 一种来司尼达的三乙胺盐结晶化合物及其制备方法 | |
CN106432275A (zh) | 一种制备治疗外科手术感染的药物头孢曲松钠晶体化合物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240219 Address after: 246004 No. 58, xiahong Road, high tech Industrial Development Zone, Anqing City, Anhui Province Applicant after: Anhui Puli Pharmaceutical Co.,Ltd. Country or region after: China Address before: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Applicant before: HAINAN POLY PHARM. Co.,Ltd. Country or region before: China Applicant before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Applicant before: Anhui Puli Pharmaceutical Co.,Ltd. |